drugset / Trial / NCT04571710
A Trial of SHR1258 in Patients With Biliary Tract Cancer
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy and safety of SHR1258 in subjects with advanced/ metastatic HER2-altered biliary tract cancers
Timeline
- Start
- 2020-11-01
- Primary completion
- 2025-06-05
- Completion
- 2025-06-05
Outcome
Outcome not reported
Stopped (Business): “The sponsor's R\&D strategy is adjusted.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyrotinib | Small molecule | 400 mg | — |